| ADE | Adverse drug event |
| ADR | Adverse drug reaction |
| ALuI | Acute lung injury |
| ALT | Alanine aminotransferase |
| AMP | Adenosine 5′-monophosphate |
| APACHE II | Acute Physiology and Chronic Health Evaluation II |
| ARDS | Acute respiratory distress syndrome |
| AST | Aspartate aminotransferase |
| BUN | Blood urea nitrogen |
| C max | Maximum plasma concentrations |
| COVID-19 | Coronavirus disease 2019 |
| CHM | Chinese herbal medicines |
| CLP | Cecal ligation and puncture |
| Cr | Creatinine |
| HLA-DR | Human leukocyte antigen-DR |
| ICU | Intensive care unit |
| LDH | Lactate dehydrogenase |
| IFN-γ | Interferon-γ |
| IL-6 | Interleukin 6 |
| LPS | Lipopolysaccharide |
| MAP | Mean arterial pressure |
| MLC | Myosin light chain |
| MLCK | Myosin light-chain kinase |
| MMP-2/9 | Matrix metalloproteinase 2/9 |
| MODS | Multiple organ dysfunction syndrome |
| OGD/R | Oxygen–glucose deprivation/reoxygenation |
| PEEP | Positive end-expiratory pressure |
| PSCC | Preventing Sepsis Campaign in China |
| QWBD | Qingwen Baidu decoction |
| ROCK | Rho-associated coil-forming protein kinase |
| SCCM | Society of Critical Care Medicine |
| SIRS | Systemic inflammatory response syndrome |
| 20(S)-protopanaxadiol type | ppd-type |
| 20(S)-protopanaxatriol type | ppt-type |
| SF | ShenFu injection |
| SM | ShengMai |
| SOCS1 | Suppressor of cytokine signaling 1 |
| SOFA | Sequential Organ Failure Assessment |
| SIRS | Systemic inflammatory response syndrome |
| t 1/2 | Half-life |
| TCM | Traditional Chinese medicine |
| TNF-α | Tumor necrosis factor-α |
| XBCQ | Xuanbai Chengqi decoction |
| XBJ | XueBiJing injection |